Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
55,705,828
-
Total 13F shares
-
19,852,133
-
Share change
-
-1,092,122
-
Total reported value
-
$39,711,772
-
Put/Call ratio
-
1184%
-
Price per share
-
$2.00
-
Number of holders
-
61
-
Value change
-
+$134,944
-
Number of buys
-
23
-
Number of sells
-
34
Institutional Holders of Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) as of Q3 2022
As of 30 Sep 2022,
Spero Therapeutics, Inc. - Common Stock, par value $0.001 per share (SPRO) was held by
61 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
19,852,133 shares.
The largest 10 holders included
Aquilo Capital Management, LLC, AWM Investment Company, Inc., BVF INC/IL, Anson Funds Management LP, Atlas Venture Associates IX, LLC, VANGUARD GROUP INC, Atlas Venture Life Science Advisors, LLC, Alphabet Inc., Rock Springs Capital Management LP, and Murchinson Ltd..
This page lists
61
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.